Navigation Links
PAREXEL Experts to Address Partnering Best Practices and Innovative Trial Design at Partnerships With CROs Conference
Date:4/22/2009

BOSTON, April 22 /PRNewswire-FirstCall/ -- Experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will present key industry topics during the 18th Annual Partnerships with CROs and Other Outsourcing Providers Conference, to be held April 28 - 30, 2009 at the Rosen Shingle Creek Hotel in Orlando, Florida. Thought leaders from PAREXEL, a sponsor of the conference, will discuss best practices in partnering for collaborative solutions and achieving innovation in study design and management through adaptive trials.

A complimentary Advisory from PAREXEL Consulting, entitled Innovating Strategic Partnerships in Regulatory Affairs, will be provided at PAREXEL's Booth #240 in the exhibit hall. Attendees can visit experts from Perceptive Informatics, a subsidiary of PAREXEL and the industry's leading eClinical solutions provider, at Booth #241 to discuss Perceptive's Randomization and Trial Supply Management (RTSM) solutions. A demonstration of Perceptive's DataLabs(R) Electronic Data Capture (EDC) system will be given at the booth. The system, focused on improving the efficiency and data quality of clinical studies, incorporates the advantages and flexibility of hybrid technology, unifying paper data entry and EDC into a single clinical data management platform.

The conference program features the following sessions, which will be presented by PAREXEL experts on Thursday, April 30 from 1:15 p.m. - 2:00 p.m.:

  • Adapting to Constant Change: How Partners are Working through the Organizational Stages--Ramita Tandon, Director of Project Management, Clinical Research Services

(Track A: Partnering for Collaborative Solutions)

  • Adaptive Clinical Trials: Innovations in Trial Design and Management--Imogene Grimes, Ph.D., Vice President, Data Sciences Strategic Services

(Track C: Raising the Bar on Quality and Patient Safety)

For more information about PAREXEL visit www.PAREXEL.com or Booths #240 and #241 at the Partnerships with CROs Conference. More information about the conference can be found at

http://www.iirusa.com/cropartners/eventhome.xml.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 51 countries around the world, and has over 9,250 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2008 as filed with the SEC on February 9, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Contacts:
    Jennifer Baird, Senior Director of Public Relations 
    PAREXEL International 
    Tel: +781-434-4409 
    Email: Jennifer.Baird@PAREXEL.com

    Rebecca Passo 
    SHIFT Communications
    Tel: +617-779-1817 
    Email: rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PAREXEL International to Present at Bank of America 2008 Smid Cap Conference
2. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
3. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
4. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
5. PAREXEL Reports Preliminary Second Quarter Results
6. PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call
7. PAREXEL Reports Second Quarter Fiscal Year 2009 Financial Results
8. PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil
9. PAREXEL International to Present at Raymond James 30th Annual Institutional Investors and the Barclays Capital Global Healthcare Conferences
10. PAREXEL Announces Date of Third Quarter Fiscal Year 2009 Earnings Release and Conference Call
11. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... Las Vegas Skin and Cancer Clinic (LVSCC) ... Friday, March 10, 2017, 4-7 pm PST. For more than six decades, LVSCC has ... the South Rancho neighborhood, has been renovated to provide medical and cosmetic dermatological products ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... healthcare automation intelligence company based in New York. , “Ensuring an intuitive, user-friendly ... workflow remains unaltered. Those two fundamental reasons are the reasons this acquisition is ...
(Date:2/28/2017)... ... 2017 , ... The role of females in the military, ... civilian life. Body image dissatisfaction is largely unexamined among female veterans, a rapidly ... of chronic mental health conditions than female civilians. Female veterans also are more ...
(Date:2/27/2017)... ... 27, 2017 , ... Bo Chen, PhD is the recipient of the 2017 ... during the Plenary Session at ASLMS 2017, the Annual Conference of the American Society ... April 5-9, 2017. , During the Plenary Session on April 7, Dr. Chen ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... the alternative health care industry, announces Chris Brandl as its New Guest Director. ... vision and purpose to corporations throughout his career. He began his professional career ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... 27, 2017 Amarantus ... BioMedical assets for potential acquisition ... contemplates capital infusion into Amarantus to assist in restructuring ... Amarantus names four new appointees to its Board of Directors and names ... Biomedical Inc. (SeD Biomedical) , a Singapore ...
(Date:2/28/2017)... The global  pulse oximeters market  is expected to reach USD 2.8 billion by ... oximeters market is anticipated to witness significant growth during the forecast period, which ... obstructive pulmonary disease (COPD), sleep apnea, cardiac arrhythmia, and ischemic conditions. ... ... Grand View Research Logo ...
(Date:2/28/2017)... 28, 2017 Nordic Nanovector ASA (OSE: NANO) announces ... presentation of the results by the company,s senior management team will ... - details below. ... 2016 was a very successful year for Nordic Nanovector. ... Betalutin®, progressed with our preclinical candidates and build the foundation of ...
Breaking Medicine Technology: